Kremenak NanoTech Revenue and Competitors
Estimated Revenue & Valuation
- Kremenak NanoTech's estimated annual revenue is currently $707k per year.
- Kremenak NanoTech's estimated revenue per employee is $101,000
Employee Data
- Kremenak NanoTech has 7 Employees.
- Kremenak NanoTech grew their employee count by -12% last year.
Kremenak NanoTech's People
Name | Title | Email/Phone |
---|
Kremenak NanoTech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 6 | 0% | N/A | N/A |
#2 | $0.7M | 7 | -12% | N/A | N/A |
#3 | $0.8M | 8 | -27% | N/A | N/A |
#4 | $0.9M | 9 | 0% | N/A | N/A |
#5 | $0.6M | 6 | 0% | N/A | N/A |
#6 | $0.6M | 6 | 0% | N/A | N/A |
#7 | $26.7M | 132 | -15% | N/A | N/A |
#8 | $0.6M | 6 | 0% | N/A | N/A |
#9 | $0.5M | 5 | 0% | N/A | N/A |
#10 | $0.7M | 7 | 17% | N/A | N/A |
What Is Kremenak NanoTech?
We create Urchin Black™ antimicrobial — the first reusable nano-spiky surface coating that physically ruptures bacteria. Manufacturers who license our patent pending coating will differentiate themselves in the market and increase their profitability. We are committed to creating innovations that will improve human and environmental health. Urchin Black™ has properties that are valuable to various industries like healthcare, marine, military, and consumer products. We are currently focused on incorporating Urchin Black™ antimicrobial throughout the healthcare setting to combat Healthcare Associated Infections, which impact 1 in 25 patients every day. Unlike conventional antimicrobials, Urchin Black™ physically kills bacteria and does not promote bacterial resistance. This is one example of how our technology will enhance everyday objects.
keywords:N/AN/A
Total Funding
7
Number of Employees
$707k
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.5M | 7 | 0% | N/A |
#2 | $0.5M | 7 | N/A | N/A |
#3 | $0.5M | 7 | -12% | N/A |
#4 | $0.5M | 7 | 40% | N/A |
#5 | $0.5M | 7 | 17% | N/A |